Topical Chemotherapy in Cutaneous T-cell Lymphoma | Zendy

Stuart R. Lessin | Zendy; Madeleine Duvic | Zendy; Joan Guitart | Zendy; Amit G. Pandya | Zendy; Bruce Strober | Zendy; Elise A. Olsen | Zendy; Christopher Hull | Zendy; Elizabeth Knobler | Zendy; Alain H. Rook | Zendy; Ellen J. Kim | Zendy; Mark F. Naylor | Zendy; David M. Adelson | Zendy; Alexa B. Kimball | Zendy; Gary S. Wood | Zendy; Uma Sundram | Zendy; Hong Wu | Zendy; Youn H. Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Topical Chemotherapy in Cutaneous T-cell Lymphoma

Author(s) -

Stuart R. Lessin,

Madeleine Duvic,

Joan Guitart,

Amit G. Pandya,

Bruce Strober,

Elise A. Olsen,

Christopher Hull,

Elizabeth Knobler,

Alain H. Rook,

Ellen J. Kim,

Mark F. Naylor,

David M. Adelson,

Alexa B. Kimball,

Gary S. Wood,

Uma Sundram,

Hong Wu,

Youn H. Kim

Publication year - 2012

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/2013.jamadermatol.541

Subject(s) - medicine , mycosis fungoides , adverse effect , lesion , lymphoma , carmustine , randomized controlled trial , dermatology , clinical endpoint , body surface area , clinical trial , surgery , chemotherapy , cyclophosphamide

To evaluate the efficacy and safety of a novel mechlorethamine hydrochloride, 0.02%, gel in mycosis fungoides. DESIGN Randomized, controlled, observer-blinded, multicenter trial comparing mechlorethamine, 0.02%, gel with mechlorethamine, 0.02%, compounded ointment. Mechlorethamine was applied once daily for up to 12 months. Tumor response and adverse events were assessed every month between months 1 and 6 and every 2 months between months 7 and 12. Serum drug levels were evaluated in a subset of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research